Abstract:LBA3559 Background: BRAF V600E mutations are present in 8-12% worldwide of patients with metastatic colorectal cancer (mCRC) and linked with a poor prognosis. Encorafenib + cetuximab (E+C) was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who received prior systemic therapy, based on data from the BEACON CRC study. Methods: This Phase II, multicenter, randomized, open-label, 2-arm study evaluated E+C vs irinotecan + cetuximab or FOLFIRI + cetuximab (control arm) in Chinese patients with BRAF V600E mutant mCRC whose disease progressed after 1 or 2 prior treatment lines in the metastatic setting. A safety lead-in initially conducted in 10 patients reported no DLTs. Eligible patients had mCRC and a BRAF V600E mutation in tumor tissue determined by a local assay before screening and centrally confirmed. Patients were randomly assigned to the doublet arm (E+C) or the control arm in a 2:1 ratio, respectively. Randomization was stratified by baseline ECOG performance status (0 vs 1) and prior use of irinotecan (yes vs no). The primary objective of the randomized phase was to compare the efficacy of E+C vs the control arm, as measured by PFS (assessed by blinded independent central review). Secondary objectives included PFS assessed by the investigator, ORR, DOR, DCR, TTR, OS, QoL, and safety and tolerability of E+C. Results of the randomized phase of the study are reported. Results: At data cut-off (19 Dec 2023), 65 patients were enrolled in the E+C arm and 32 in the control arm. Median patient age was 56 years, the primary cancer site was the left colon in 56.7% of patients, 48.5% had metastases to ≥3 organs, 56.7% had liver metastases, 77.3% received one prior metastatic treatment, and 22.7% received 2 prior metastatic treatments. Results are shown below for E+C vs the control arm, respectively. Median PFS assessed by BICR was 4.2 mo vs 2.5 mo (HR 0.37; 95% CI: 0.20, 0.68; P=0.0004). Median OS was 11.6 mo vs 8.2 mo (HR for death 0.55; 95% CI: 0.31, 0.99). Confirmed ORR was 24.6% (95% CI: 14.8, 36.9) vs 6.3% (95% CI: 0.8, 20.8). Treatment emergent adverse events (TEAEs) of grade 3 or higher occurred in 47.7% vs 51.9% of patients. Treatment-related grade 3 or higher occurred in 24.6% and 44.4% of patients. The most frequent TEAEs were anemia (30.8% vs 37%), vomiting (26.2% vs 33.3%), rash (24.6% vs 29.6%), weight loss (23.1% vs 18.5%), hypoalbuminemia (21.5% vs 22.2%), and melanocytic naevus (21.5% vs 0%). Three patient deaths were reported during treatment: unknown cause (n=1) and pneumonia (n=1) in the E+C arm and septic shock (n=1) in the control arm. Conclusions: Treatment with a combination of encorafenib and cetuximab is effective and well tolerated in Chinese patients with BRAF V600E mutant mCRC, resulting in a significantly longer PFS than standard therapies. These results are consistent with those previously reported in the BEACON study. Clinical trial information: NCT05004350 .

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer

Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study

Rechallenge with BRAF and Anti-Egfr Inhibitors in Patients with Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib with or Without Binimetinib: A Case Series.

BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib

Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.

CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC

Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report

A Phase Ib-Ii Study of Dabrafenib, Trametinib, Cetuximab Plus Irinotecan in Patients with BRAF Mutant Metastatic Colorectal Cancer: Subgroup Analysis and Biomarker Identification.

BRAF and EGFR Inhibitors Synergize to Increase Cytotoxic Effects and Decrease Stem Cell Capacities in BRAF(V600E)-mutant Colorectal Cancer Cells.

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

BCL-X L inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series